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The frequent use of nonsteroidal anti-inflammatory drugs (NSAID) in
combination with gentamicin poses the additional risk of nephrotoxic
renal failure. Cyclooxygenase-1 (COX-1) is the main enzyme respon-
sible for the synthesis of renal vasodilator prostaglandins, while COX-
2 participates predominantly in the inflammatory process. Both are
inhibited by non-selective NSAID such as indomethacin. Selective
COX-2 inhibitors such as rofecoxib seem to have fewer renal side
effects than non-selective inhibitors. The objective of the present
study was to determine whether the combined use of rofecoxib and
gentamicin can prevent the increased renal injury caused by gentami-
cin and indomethacin. Male Wistar rats (250-300 g) were treated with
gentamicin (100 mg/kg body weight, ip, N = 7), indomethacin (5 mg/
kg, orally, N = 7), rofecoxib (1.4 mg/kg, orally, N = 7), gentamicin +
rofecoxib (100 and 1.4 mg/kg, respectively) or gentamicin + indo-
methacin (100 and 5 mg/kg, respectively, N = 8) for 5 days. Creatinine
clearance and α-glutathione-S-transferase concentrations were used
as markers of renal injury. Animals were anesthetized with ether and
sacrificed for blood collection. The use of gentamicin plus indometh-
acin led to worsened renal function (0.199 ± 0.019 ml/min), as
opposed to the absence of a nephrotoxic effect of rofecoxib when
gentamicin plus rofexicob was used (0.242 ± 0.011 ml/min). These
results indicate that COX-2-selective inhibitors can be used as an
alternative treatment to conventional NSAID, especially in situations
in which risk factors for nephrotoxicity are present.
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• Acute renal failure
Introduction
The interaction between gentamicin and
other nephrotoxic drugs such as nonsteroidal
anti-inflammatory drugs (NSAID) has not
been emphasized despite its extreme clinical
relevance. Gentamicin is often prescribed to
patients with infections and with other symp-
tomatic co-morbidities such as pain and in-
flammation, situations that require the appli-
cation of anti-inflammatory drugs.
Treatment with gentamicin and NSAID
is known to result in nephrotoxicity and the
exact mechanism is still not completely un-
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derstood. Some studies have provided evi-
dence of an increased synthesis of renal
vasodilatory prostaglandins in animals treated
with gentamicin (1), an effect probably rep-
resenting a compensatory mechanism for the
prevention of a reduction in glomerular fil-
tration rate during the development of gen-
tamicin-induced nephrotoxicity. NSAID non-
specifically inhibit cyclooxygenase (COX),
an enzyme involved in renal prostaglandin
synthesis, and this inhibition is believed to
promote compensatory vasodilatory disequi-
librium, leading to a deterioration of glo-
merular filtration rate (1,2).
The discovery in 1991 of the existence of
two COX isoforms (COX-1 and COX-2) and
of their distinct physiological roles (3,4) per-
mitted the development of COX-2-selective
NSAID inhibitors, potentially revolutionary
drugs able to alleviate COX-2-induced symp-
toms without the gastric and renal side ef-
fects caused by the inhibition of COX-1.
The aim of the present study was to deter-
mine whether the combined use of the COX-
2-selective inhibitor rofecoxib and gentami-
cin can prevent the potentiation of renal
injury caused by gentamicin when given with
indomethacin. For this purpose, two groups
of rats were studied: one receiving gentami-
cin and indomethacin and the other receiv-
ing gentamicin and rofecoxib.
Material and Methods
Male Wistar rats weighing 250-300 g and
receiving water and ration ad libitum were
randomly divided into six groups submitted
to 5 days of treatment with the following
drugs: saline group (N = 8), 0.1 ml 0.9%
NaCl intraperitoneally (ip); gentamicin group
(N = 7), gentamicin (Schering-Plough Labo-
ratory, São Paulo, SP, Brazil) 100 mg/kg
body weight, ip; rofecoxib group (N = 7),
rofecoxib (Merck Sharp & Dohme Labora-
tory, São Paulo, SP, Brazil) 1.4 mg/kg body
weight, orally; indomethacin group (N = 7),
indomethacin (Merck Sharp & Dohme Labo-
ratory) 5 mg/kg body weight, orally; gen-
tamicin + rofecoxib group (N = 7), gentami-
cin plus rofecoxib at doses of 100 and 1.4
mg/kg, respectively; gentamicin + indometh-
acin group (N = 8), gentamicin plus indo-
methacin at doses of 100 and 5 mg/kg, re-
spectively.
The indomethacin and rofecoxib doses
used in the present study were similar to the
therapeutic doses used in patients.
Experimental design
After the last dose, all animals were placed
in metabolic cages for 24 h, with water and
ration available ad libitum. The animals were
then anesthetized with ether for blood collec-
tion by puncture of the abdominal aorta and
sacrificed according to the norms for didactic-
scientific practice of animal vivisection. The
kidneys were removed and placed in 35%
formaldehyde for histological analysis.
Blood and urine samples were used for
the determination of creatinine clearance by
the modified Jaffe method.
A 400-µl urine sample was used to quan-
tify urinary α-glutathione-S-transferase (α-
GST), an enzyme marker for the identifica-
tion of proximal tubular injury. After collec-
tion, a urine stabilizer (100 µl thiomersal and
sodium azide per 400 µl urine) was added to
the sample, which was kept at -20oC for later
determination. α-GST was quantified by
ELISA using the Biotrin Rat Alpha-GST kit
(Biotrin International, Dublin, Ireland).
Determination of creatinine clearance by the
Jaffe method
Plasma was deproteinized for the deter-
mination of serum creatinine with a spectro-
photometer at 520 nm absorbance. For uri-
nary creatinine, absorbance was measured
as described above. Creatinine clearance was
calculated by multiplying urinary creatinine
by 24-h urinary flow (in ml/min), divided by
plasma creatinine.
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Quantification of urinary α-glutathione-S-
transferase by ELISA
The samples were diluted 1:5 in sample
diluent (Biotrin Rat α-GST), i.e., 100 µl
urine per 400 µl diluent. The urine samples
were then added to uncovered plates con-
taining rat anti-α-GST IgG antibody, on
which the α-GST in the sample was captured
by the anti-α-GST antibody attached to the
plate. The following substances were then
added, with the plates being washed be-
tween each new addition: enzymatic rat anti-
α-GST IgG conjugate, enzyme-conjugated
anti-IgG antibody, and an enzyme choleri-
genic substrate. The intensity of the resulting
color was proportional to the amount of α-
GST present in the sample. Finally, absorb-
ance was measured with an ELISA plate
reader using a 450-nm filter.
Renal histology
For histological evaluation of the renal
tubular structure by light microscopy, the
kidneys were fixed in 35% formaldehyde,
paraffin-embedded, sectioned, and prepared
on slides stained with hematoxylin and eosin.
Statistical analysis
Statistical analyses were performed us-
ing the SPSS software, version 8.0 (SPSS
Inc., Chicago, IL, USA, 1989-1997).
The Levene test used analysis of variance
homogeneity between groups. Multiple com-
parisons between creatinine clearance/100 g
(CrCl/100 g) body weight and α-GST, based
on the mean values obtained for each group,
were performed using the Student t-test and
the Mann-Whitney test, with the level of
significance set at P < 0.05.
Results
As shown in Table 1, gentamicin treat-
ment led to a significant reduction in CrCl/
100 g, while urinary flow was constant, sug-
gesting the occurrence of non-oliguric acute
renal failure of nephrotoxic origin. The sa-
line group was within the normal range re-
ported in previous studies (5).
Treatment with the anti-inflammatory
drugs rofecoxib and indomethacin did not
lead to significant alterations in renal func-
tion, with creatinine clearance and urinary
flow being similar to those observed for the
control group.
Drug combination led to a significant
decrease in CrCl/100 g in the gentamicin +
rofecoxib group compared to the saline and
rofecoxib groups, without alterations in uri-
nary flow. The gentamicin + indomethacin
combination caused a significant reduction
in CrCl/100 g with maintenance of urinary
flow compared to the saline, gentamicin and
indomethacin groups. This result demon-
strates that the combination of a nonspecific
COX inhibitor (indomethacin) and gentami-
cin not only induces nephrotoxic acute renal
failure but also potentiates the nephrotoxic
effect of the aminoglycoside, as shown by
the comparison with the gentamicin group.
This was not observed for the gentamicin
and rofecoxib combination.
No significant differences were observed
between the gentamicin + indomethacin and
gentamicin + rofecoxib groups. In addition,
Table 1. Effect of gentamicin, rofecoxib and indomethacin on renal function and
creatinine clearance parameters.
Groups U (ml/min) CrU (mg/dl) CrP (mg/dl) CrCl/100 g
Saline 0.0074 ± 0.0009 100 ± 8 0.416 ± 0.037 0.679 ± 0.070
Gentamicin 0.0057 ± 0.0011 93 ± 16 0.601 ± 0.073 0.259 ± 0.018*
Rofecoxib 0.0062 ± 0.0008 91 ± 12 0.337 ± 0.018 0.580 ± 0.054
Indomethacin 0.0057 ± 0.0005 111 ± 9 0.387 ± 0.024 0.620 ± 0.098
Gentamicin + 0.0045 ± 0.0005 91 ± 7 0.579 ± 0.038 0.242 ± 0.011*+
rofecoxib
Gentamicin + 0.0052 ± 0.0009 70 ± 9 0.657 ± 0.060 0.199 ± 0.019*‡§
indomethacin
Data are reported as means ± SEM. U = urinary flow; CrU = urinary creatinine; CrP =
plasma creatinine; CrCl = creatinine clearance.
*P < 0.05 vs saline; +P < 0.05 vs rofecoxib; ‡P < 0.05 vs indomethacin; §P < 0.05 vs
gentamicin (Mann-Whitney and t-test).
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significance was close to α (P = 0.054), with
an unfavorable tendency towards renal tox-
icity being observed for the gentamicin +
indomethacin group.
As shown in Table 2, the gentamicin
group showed a statistically significant in-
crease in urinary α-GST compared to the
control group, indicating gentamicin-induced
proximal tubular damage. Similar to the
creatinine clearance results, the urinary α-
GST concentrations for the rofecoxib and
indomethacin groups were similar to those
for the control group, indicating that neither
NSAID caused proximal tubular renal dam-
age.
A significant difference in α-GST was also
observed when the NSAID were used in com-
bination with gentamicin, with the gentamicin
+ rofecoxib and gentamicin + indomethacin
groups showing higher urinary α-GST levels
than the control group. This increase in urinary
α-GST levels upon combined treatment with
these two types of drugs indicates that gen-
tamicin was responsible for the occurrence of
renal injury, since neither NSAID alone
caused any proximal tubular damage.
An increase in urinary α-GST excretion
was observed for the gentamicin + rofecoxib
group compared to the rofecoxib group. On
the other hand, no significant difference in
urinary α-GST was observed between the
gentamicin + indomethacin and indometh-
acin groups. These results suggest a discrete
worsening in gentamicin-induced nephro-
toxic renal failure when a nonspecific COX
inhibitor (indomethacin) instead of a COX-
2-selective inhibitor (rofecoxib) was used in
combination.
Histology
Histological analysis of kidney sections
showed varying morphological patterns rang-
ing from the absence of histological alter-
ations to minimal changes. It should be noted
that the observed histological patterns did
not correlate with type of treatment and there-
fore could not be used to define a histologi-
cal profile for the kidneys of animals submit-
ted to saline, gentamicin or the drug combi-
nations studied. Thus, the histological anal-
ysis employed here was probably not sensi-
tive enough to detect possible structural al-
terations caused by the different treatments
or functional changes induced by drug treat-
ment, at the time studied.
Discussion
The results of the present study suggest
that the selective inhibition of COX-2 appar-
ently does not cause further damage in addi-
tion to the nephrotoxic effect caused by gen-
tamicin. As expected, all rats treated with
gentamicin showed a reduction in renal func-
tion, including those receiving gentamicin in
combination with NSAID.
Gentamicin-induced nephrotoxicity is a
well-documented event involving some func-
tional and cellular mechanisms such as glo-
merular lesions that interfere with glomeru-
lar hemodynamics, and altered tubular trans-
port, with the injury ranging from solely
functional lesions to the occurrence of ne-
crosis (6).
In the present study, the administration
of gentamicin caused a significant reduction
in glomerular filtration rate, as identified by
reduced creatinine clearance. Experimental
studies have demonstrated that this amino-
glycoside causes a significant reduction in
Table 2. Effect of gentamicin, rofecoxib and indo-
methacin on urinary α-GST.
Groups (N) α-GST (µg/l)
Saline (7) 13.74 ± 0.42
Gentamicin (7) 23.10 ± 3.59*
Rofecoxib (8) 13.54 ± 0.29
Indomethacin (6) 16.23 ± 2.45
Gentamicin + rofecoxib (8) 20.96 ± 2.92*+
Gentamicin + indomethacin (8) 21.35 ± 2.34*
Data are reported as means ± SEM.
*P < 0.05 vs saline; +P < 0.05 vs rofecoxib
(Mann-Whitney and t-test).
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Kf and an increase in the resistance of affer-
ent and efferent arterioles, temporarily asso-
ciated with a 30 to 50% reduction in global
renal and nephron filtration (7,8). This re-
duced filtration seems essentially to be re-
lated to an obstructive renal intratubular
mechanism which reduces intraluminal flow,
a defect affecting most functional renal tu-
bules. This altered flow, in turn, may trigger
the decline in final excretion (9). In addition
to the obstructive component, glomerular
filtrate leakage through the damaged tubular
epithelium may also contribute to the de-
crease in glomerular filtration.
The decrease in creatinine clearance cor-
responds to the reduction in the glomerular
filtration rate mentioned above, indicating
that the hemodynamic mechanism estab-
lished here reproduced the events described
above, including a reduction in Kf, obstruc-
tion and tubular leakage.
In addition to causing changes in filtra-
tion, gentamicin has been shown to induce
proximal tubular injury, with the damage
ranging from alterations in tubular reabsorp-
tion to necrosis of proximal tubule cells. The
mechanisms leading to this event remain
unclear, but interactions of the drug with the
cell membrane and intracytoplasmic or-
ganelles cannot be ruled out (10).
Therefore, enzymatic markers naturally
excreted during organ damage have been
used in addition to the determination of creati-
nine clearance. The best known markers are
N-acetyl-beta-D-glucosaminidase (NAG),
alanine-aminopeptidase and ß2-microglobu-
lin (11). Comparative studies regarding the
predictive value of these enzymes for the
evaluation of gentamicin nephrotoxicity have
revealed the efficacy and superiority of NAG
over the other markers, a fact attributable to
the proportional relationship between NAG
and gentamicin-induced renal damage (11).
Due to its advantages in the identifica-
tion of renal injury, α-GST was used in the
present study as a complementary parameter
for the evaluation of proximal tubular dam-
age. The results showed an elevated concen-
tration of this enzyme in the groups submit-
ted to treatment with gentamicin alone or in
combination with the anti-inflammatory
drugs. These findings confirm the damaging
effects of this aminoglycoside in the proxi-
mal tubular region, probably as a result of
the cell mechanisms discussed at the begin-
ning of this section.
Similar urinary α-GST levels were ob-
served for the groups receiving only anti-
inflammatory drugs and the control group,
similar to the results obtained for creatinine
clearance. Taken together, these findings
suggest that the anti-inflammatory drugs used
in the present study did not cause functional
alterations or tubular damage in these ani-
mals, thus confirming previous studies on
the toxicity of these drugs.
On the other hand, the decline in glo-
merular filtration rate may stimulate the syn-
thesis of vasodilatory prostaglandins that act
in the reduction of afferent arteriolar resis-
tance and thus contribute to the reestablish-
ment of renal plasma flow. The use of NSAID
may inhibit this additional protective mech-
anism, since afferent arteriolar tonus is in-
creased in the absence of dilatory prosta-
glandins, leading to a decline in renal plasma
flow associated with a reduced Kf, a situa-
tion that results in a dramatic reduction in
glomerular filtration rate (12).
Similar to gentamicin, other drugs also
show preferential toxicity for the kidney,
including the COX-inhibiting NSAID such
as indomethacin. In addition to nephrotoxic-
ity, indomethacin also presents gastrointes-
tinal toxicity. Gastric toxicity is one of the
most common side effects and manifests in
the form of dyspepsia, gastritis and peptic
ulcers (13).
All the gastric and renal effects of NSAID
are directly related to their potential for in-
hibiting the COX-1 isoform, which is consti-
tutively expressed in the kidney. The inhibi-
tion of COX-1 is in turn related to the inhibi-
tion of the synthesis of renal vasodilatory
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prostaglandins such as PGE2 and PGI2, caus-
ing the above described effects.
In the present study, indomethacin treat-
ment alone did not alter renal function as
determined by creatinine clearance. Further-
more, no significant increase in urinary α-
GST levels was observed, thus excluding
any proximal tubular damage. This finding
confirms previous studies which reported
that the toxic effects of this drug are limited
to situations of pre-existing damage, or when
the drug is administered in combination with
other nephrotoxic drugs.
As described previously (2,14) and con-
firmed in the present study, exclusive ad-
ministration of gentamicin resulted in a
marked reduction in glomerular filtration
rate, as indicated by a significantly lower
creatinine clearance compared to the control
group. When gentamicin was administered
in combination with indomethacin, a signifi-
cantly higher decrease in creatinine clear-
ance was observed compared to the group
treated with gentamicin alone.
Evaluation of the nephrotoxicity of gen-
tamicin administered in combination with an
NSAID showed that the NSAID potentiated
the reduction in urinary concentrating ca-
pacity observed with gentamicin alone after
10 days of treatment (1). In addition, animals
treated with gentamicin alone showed a spe-
cific increase in PGE2, a renal vasodilator.
These results suggest that the NSAID im-
pairs the PGE2-mediated compensatory va-
sodilatory mechanism for the maintenance
of glomerular filtration rate and renal blood
flow, thus extending the renal damage caused
by gentamicin (1).
The results of the present study suggest
that, although the administration of indo-
methacin alone did not affect normal renal
function, its combination with gentamicin
potentiated renal damage, in view of the
decline in glomerular filtration rate evidenced
by the reduced creatinine clearance in the
gentamicin group and intensified by the ad-
ministration of indomethacin. Thus, indo-
methacin may have caused the inhibition of
vasodilatory prostaglandins that physiologi-
cally act on the preservation of renal plasma
flow in this model of acute renal failure. It
should be emphasized here that COX-1 is
known to promote renal vasodilatation, es-
pecially in the presence of other renal dam-
age-causing factors (e.g., aminoglycosides).
Another mechanism whereby nonselec-
tive NSAID inhibitors of COX may facilitate
vasoconstriction and extend ischemic lesions
involves an increase in the formation of va-
soconstrictive metabolites derived from ara-
chidonic acid, since the inhibition of COX
makes a larger amount of this acid available
for metabolization through COX-independ-
ent routes, thus producing a series of potent
vasoconstrictors (15,16).
Both COX-2 and COX-1, although con-
stitutively expressed in some parts of the
kidney (macula densa, interstitial medullary
and epithelial cells adjacent to the thick cor-
tical ascending segment), are considered to
be induced during inflammatory events
(17,18). However, little is known thus far
about their action under conditions of renal
deficiency.
In the present study, the exclusive use of
a COX-2-selective inhibitor (rofecoxib) did
not alter renal function. Therefore, the re-
sults obtained for the rofecoxib and indo-
methacin groups indicate that the inhibition
of prostaglandin synthesis in healthy ani-
mals by both anti-inflammatory drugs does
not affect normal renal function.
In contrast, the combination of gentami-
cin and the COX-2-selective NSAID led to a
reduction in creatinine clearance similar to
that caused by gentamicin alone and slightly
less intense than that observed for the gen-
tamicin + indomethacin group. This result
suggests that the selective inhibition of COX-
2 induced by the selective NSAID did not
interfere with the gentamicin-induced
mechanisms of nephrotoxicity nor did it ex-
ert other damaging effects on renal function.
Although no marked difference in renal
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function was observed between animals
treated with gentamicin and animals treated
with the nonspecific or COX-2-selective
NSAID, renal injury was more intense when
the nonspecific NSAID was used in combi-
nation. A possible explanation for this result
is the preservation of the synthesis of vasodi-
latory prostaglandins such as PGE2 by the
COX-2-selective inhibitors, stimulated by
gentamicin.
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